Table of Content
1. INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL ALBUTEROL MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2. MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL ALBUTEROL MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 EPIDEMIOLOGY
2.2.12 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.13 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL ALBUTEROL MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3. MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4. EXECUTIVE SUMMARY
5. PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S FIVE FORCES MODEL
6. INDUSTRY INSIGHTS
6.1 PATENT ANALYSIS
6.1.1 PATENT LANDSCAPE
6.1.2 USPTO NUMBER
6.1.3 PATENT EXPIRY
6.1.4 EPIO NUMBER
6.1.5 PATENT STRENGTH AND QUALITY
6.1.6 PATENT CLAIMS
6.1.7 PATENT CITATIONS
6.1.8 PATENT LITIGATION AND LICENSING
6.1.9 FILE OF PATENT
6.1.10 PATENT RECEIVED CONTRIES
6.1.11 TECHNOLOGY BACKGROUND
6.2 DRUG TREATMENT RATE BY MATURED MARKETS
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATES
6.4 PATIENT FLOW DIAGRAM
6.5 KEY PRICING STRATEGIES
6.6 KEY PATIENT ENROLLMENT STRATEGIES
6.7 INTERVIEWS WITH SPECIALIST
6.8 OTHER KOL SNAPSHOTS
7. EPIDEMIOLOGY
7.1 INCIDENCE OF ALL BY GENDER
7.2 TREATMENT RATE
7.3 MORTALITY RATE
7.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL
7.5 PATIENT TREATMENT SUCCESS RATES
8. MERGERS AND ACQUISITION
8.1 LICENSING
8.2 COMMERCIALIZATION AGREEMENTS
9. REGULATORY FRAMEWORK
9.1 REGULATORY APPROVAL PROCESS
9.2 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL
9.3 REGULATORY APPROVAL PATHWAYS
9.4 LICENSING AND REGISTRATION
9.5 POST-MARKETING SURVEILLANCE
9.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES
10. PIPELINE ANALYSIS
10.1 CLINICAL TRIALS AND PHASE ANALYSIS
10.2 DRUG THERAPY PIPELINE
10.3 PHASE III CANDIDATES
10.4 PHASE II CANDIDATES
10.5 PHASE I CANDIDATES
10.6 OTHERS (PRE-CLINICAL AND RESEARCH)
TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL ALBUTEROL MARKET
Company Name Therapeutic Area Product Name Generic Name Type Indication Originator Development Status No.of Subject Filed/Approval Date Expected Launch Date
XX XX XX XX XX XX XX XX XX XX XX
XX XX XX XX XX XX XX XX XX XX XX
XX XX XX XX XX XX XX XX XX XX XX
XX XX XX XX XX XX XX XX XX XX XX
XX XX XX XX XX XX XX XX XX XX XX
XX XX XX XX XX XX XX XX XX XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE
Phase Number of Projects Number of Products
Preclinical/Research Projects XX XX
Clinical Development XX XX
Phase I XX XX
Phase II XX XX
Phase III XX XX
U.S. Filed/Approved But Not Yest Marketed XX XX
Total XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE
Therapeutic Area Preclinical/ Research Project Number of Clinical Projects by Phase Total ClinicalPhase Projects
Phase I Phase II Phase III U.S. Filed/ Approved
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
Total Projects XX XX XX XX XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE
Technology Preclinical/ Research Project Number of Clinical Projects by Phase Total Clinical Phase Projects
Phase I Phase II Phase III U.S. Filed/ Approved
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
XX XX XX XX XX XX XX
Total Projects XX XX XX XX XX XX
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
FIGURE 1 TOP ENTITIES BASED ON R&D GLANCE FOR GLOBAL ALBUTEROL MARKET
Sources: Press Releases, Annual Reports, SEC Filings, Investor Presentations, Other Government Sources, Analysis Based on Inputs from Secondary, Expert Interviews
11. MARKETED DRUG ANALYSIS
11.1 DRUG
11.1.1 BRAND NAME
11.1.2 GENERICS NAME
11.2 THERAPEUTIC INDICATION
11.3 PHARACOLOGICAL CLASS OD THE DRUG
11.4 DRUG PRIMARY INDICATION
11.5 MARKET STATUS
11.6 MEDICATION TYPE
11.7 DRUG DOSAGES FORM
11.8 DOSAGES AVAILABILITY
11.9 PACKAGING TYPE
11.10 DRUG ROUTE OF ADMINISTRATION
11.11 DOSING FREQUENCY
11.12 DRUG INSIGHT
11.13 AN OVERVIEW OF THE DRUG DEVELOPMENT ACTIVITIES SUCH AS REGULATORY MILSTONE, SAFETY DATA AND EFFICACY DATA, MARKET EXCLUSIVITY DATA.
11.13.1 FORECAST MARKET OUTLOOK
11.13.2 CROSS COMPETITION
11.13.3 THERAPEUTIC PORTFOLIO
11.13.4 CURRENT DEVELOPMENT SCENARIO
12. MARKET ACCESS
12.1 10-YEAR MARKET FORECAST
12.2 CLINICAL TRIAL RECENT UPDATES
12.3 ANNUAL NEW FDA APPROVED DRUGS
12.4 DRUGS MANUFACTURER AND DEALS
12.5 MAJOR DRUG UPTAKE
12.6 CURRENT TREATMENT PRACTICES
12.7 IMPACT OF UPCOMING THERAPY
13. R & D ANALYSIS
13.1 COMPARATIVE ANALYSIS
13.2 DRUG DEVELOPMENTAL LANDSCAPE
13.3 IN-DEPTH INSIGHTS ON REGULATORY MILESTONES
13.4 THERAPEUTIC ASSESSMENT
13.5 ASSET-BASED COLLABORATIONS AND PARTNERSHIPS
14. GLOBAL ALBUTEROL MARKET, BY PRODUCT TYPE
(NOTE: MARKET VALUE, MARKET VOLUME AND ASP WILL BE PROVIDED FOR ALL SEGMENTS AND SUB-SEGMENTS )
14.1 OVERVIEW
14.2 ALBUTEROL SULFATE INHALATION SOLUTION 0.083%
14.3 ALBUTEROL SULFATE INHALATION SOLUTION 0.042%
14.4 ALBUTEROL SULFATE INHALATION SOLUTION 0.021%
14.5 ALBUTEROL SULFATE INHALATION SOLUTION 0.5%
14.6 OTHERS
15. GLOBAL ALBUTEROL MARKET, BY DRUG TYPE
15.1 OVERVIEW
15.2 BRANDED
15.2.1 ACCUNEB
15.2.2 PROAIR DIGIHALER
15.2.3 PROAIR HFA
15.2.4 PROAIR RESPICLICK
15.2.5 PROVENTIL
15.2.6 PROVENTIL HFA
15.2.7 RELION VENTOLIN HFA
15.2.8 VENTOLIN
15.2.9 VENTOLIN HFA
15.2.10 OTHER
15.3 GENERICS
16. GLOBAL ALBUTEROL MARKET, BY MODE OF PURCHASE
16.1 OVERVIEW
16.2 OVER THE COUNTER (OTC)
16.3 PRESCRIPTION (RX)
17. GLOBAL ALBUTEROL MARKET, BY DOSAGES
17.1 OVERVIEW
17.2 ORAL
17.2.1 TABLET
17.2.1.1. 2 MG
17.2.1.2. 4 MG
17.2.2 SYRUP
17.3 INHALATION
17.3.1 METERED-DOSE INHALERS (MDIS)
17.3.1.1. 90 MCG
17.3.1.2. 100 MCG
17.3.2 DRY POWDER INHALERS (DPIS)
17.3.2.1. 50 MCG
17.3.2.2. 100 MCG
17.3.2.3. 200 MCG
17.4 NEBULIZATION
18. GLOBAL ALBUTEROL MARKET, BY DISEASE
18.1 OVERVIEW
18.2 ASTHMA
18.3 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
18.3.1 CHRONIC BRONCHITIS
18.3.2 EMPHYSEMA
18.4 OTHERS
19. GLOBAL ALBUTEROL MARKET, BY PATIENT TYPE
19.1 OVERVIEW
19.2 PEDIATRIC
19.3 ADULT
20. GLOBAL ALBUTEROL MARKET, BY END USER
20.1 OVERVIEW
20.2 HOSPITAL & CLINICS
20.3 SPECIALTY CENTRES
20.4 AMBULATORYSURGICAL CENTER
20.5 HOME HEALTHCARE
20.6 OTHERS
21. GLOBAL ALBUTEROL MARKET, BY DISTRIBUTION CHANNEL
21.1 OVERVIEW
21.2 DIRECT TENDER
21.3 RETAIL PAHRMACIES
21.3.1 HOSPITAL ASSOCIATED PAHRMACIES
21.3.2 RETAIL PAHRMACIES
21.3.3 ONLINE PAHRMACIES
21.3.4 OTHER
21.4 OTHERS
22. GLOBAL ALBUTEROL MARKET, BY GEOGRAPHY
22.1 GLOBAL ALBUTEROL MARKET (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
22.1.1 NORTH AMERICA
22.1.1.1. U.S.
22.1.1.2. CANADA
22.1.1.3. MEXICO
22.1.2 EUROPE
22.1.2.1. GERMANY
22.1.2.2. FRANCE
22.1.2.3. U.K.
22.1.2.4. HUNGARY
22.1.2.5. LITHUANIA
22.1.2.6. AUSTRIA
22.1.2.7. IRELAND
22.1.2.8. NORWAY
22.1.2.9. POLAND
22.1.2.10. ITALY
22.1.2.11. SPAIN
22.1.2.12. RUSSIA
22.1.2.13. TURKEY
22.1.2.14. BELGIUM
22.1.2.15. NETHERLANDS
22.1.2.16. SWITZERLAND
22.1.2.17. REST OF EUROPE
22.1.3 ASIA-PACIFIC
22.1.3.1. JAPAN
22.1.3.2. CHINA
22.1.3.3. SOUTH KOREA
22.1.3.4. INDIA
22.1.3.5. AUSTRALIA
22.1.3.6. SINGAPORE
22.1.3.7. THAILAND
22.1.3.8. MALAYSIA
22.1.3.9. INDONESIA
22.1.3.10. PHILIPPINES
22.1.3.11. VIETNAM
22.1.3.12. REST OF ASIA-PACIFIC
22.1.4 SOUTH AMERICA
22.1.4.1. BRAZIL
22.1.4.2. ARGENTINA
22.1.4.3. PERU
22.1.4.4. REST OF SOUTH AMERICA
22.1.5 MIDDLE EAST AND AFRICA
22.1.5.1. SOUTH AFRICA
22.1.5.2. SAUDI ARABIA
22.1.5.3. UAE
22.1.5.4. EGYPT
22.1.5.5. KUWAIT
22.1.5.6. ISRAEL
22.1.5.7. REST OF MIDDLE EAST AND AFRICA
22.1.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
23. GLOBAL ALBUTEROL MARKET, COMPANY LANDSCAPE
23.1 COMPANY SHARE ANALYSIS: GLOBAL
23.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
23.3 COMPANY SHARE ANALYSIS: EUROPE
23.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
23.5 MERGERS & ACQUISITIONS
23.6 NEW PRODUCT DEVELOPMENT & APPROVALS
23.7 EXPANSIONS
23.8 REGULATORY CHANGES
23.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
24. GLOBAL ALBUTEROL MARKET, SWOT AND DBMR ANALYSIS
25. GLOBAL ALBUTEROL MARKET, COMPANY PROFILE
25.1 TEVA PHARMACEUTICALS
25.1.1 COMPANY OVERVIEW
25.1.2 REVENUE ANALYSIS
25.1.3 GEOGRAPHIC PRESENCE
25.1.4 PRODUCT PORTFOLIO
25.1.5 RECENT DEVELOPEMNTS
25.2 GLAXOSMITHKLINE (GSK)
25.2.1 COMPANY OVERVIEW
25.2.2 REVENUE ANALYSIS
25.2.3 GEOGRAPHIC PRESENCE
25.2.4 PRODUCT PORTFOLIO
25.2.5 RECENT DEVELOPEMNTS
25.3 MYLAN PHARMACEUTICALS (PART OF VIATRIS)
25.3.1 COMPANY OVERVIEW
25.3.2 REVENUE ANALYSIS
25.3.3 GEOGRAPHIC PRESENCE
25.3.4 PRODUCT PORTFOLIO
25.3.5 RECENT DEVELOPEMNTS
25.4 CIPLA
25.4.1 COMPANY OVERVIEW
25.4.2 REVENUE ANALYSIS
25.4.3 GEOGRAPHIC PRESENCE
25.4.4 PRODUCT PORTFOLIO
25.4.5 RECENT DEVELOPEMNTS
25.5 SUN PHARMACEUTICAL INDUSTRIES
25.5.1 COMPANY OVERVIEW
25.5.2 REVENUE ANALYSIS
25.5.3 GEOGRAPHIC PRESENCE
25.5.4 PRODUCT PORTFOLIO
25.5.5 RECENT DEVELOPEMNTS
25.6 NOVARTIS (SANDOZ)
25.6.1 COMPANY OVERVIEW
25.6.2 REVENUE ANALYSIS
25.6.3 GEOGRAPHIC PRESENCE
25.6.4 PRODUCT PORTFOLIO
25.6.5 RECENT DEVELOPEMNTS
25.7 ASTRAZENECA
25.7.1 COMPANY OVERVIEW
25.7.2 REVENUE ANALYSIS
25.7.3 GEOGRAPHIC PRESENCE
25.7.4 PRODUCT PORTFOLIO
25.7.5 RECENT DEVELOPEMNTS
25.8 PFIZER
25.8.1 COMPANY OVERVIEW
25.8.2 REVENUE ANALYSIS
25.8.3 GEOGRAPHIC PRESENCE
25.8.4 PRODUCT PORTFOLIO
25.8.5 RECENT DEVELOPEMNTS
25.9 LUPIN PHARMACEUTICALS
25.9.1 COMPANY OVERVIEW
25.9.2 REVENUE ANALYSIS
25.9.3 GEOGRAPHIC PRESENCE
25.9.4 PRODUCT PORTFOLIO
25.9.5 RECENT DEVELOPEMNTS
25.10 DR. REDDY'S LABORATORIES
25.10.1 COMPANY OVERVIEW
25.10.2 REVENUE ANALYSIS
25.10.3 GEOGRAPHIC PRESENCE
25.10.4 PRODUCT PORTFOLIO
25.10.5 RECENT DEVELOPEMNTS
25.11 SANOFI
25.11.1 COMPANY OVERVIEW
25.11.2 REVENUE ANALYSIS
25.11.3 GEOGRAPHIC PRESENCE
25.11.4 PRODUCT PORTFOLIO
25.11.5 RECENT DEVELOPEMNTS
25.12 AMNEAL PHARMACEUTICALS
25.12.1 COMPANY OVERVIEW
25.12.2 REVENUE ANALYSIS
25.12.3 GEOGRAPHIC PRESENCE
25.12.4 PRODUCT PORTFOLIO
25.12.5 RECENT DEVELOPEMNTS
25.13 APOTEX
25.13.1 COMPANY OVERVIEW
25.13.2 REVENUE ANALYSIS
25.13.3 GEOGRAPHIC PRESENCE
25.13.4 PRODUCT PORTFOLIO
25.13.5 RECENT DEVELOPEMNTS
25.14 PERRIGO
25.14.1 COMPANY OVERVIEW
25.14.2 REVENUE ANALYSIS
25.14.3 GEOGRAPHIC PRESENCE
25.14.4 PRODUCT PORTFOLIO
25.14.5 RECENT DEVELOPEMNTS
25.15 ZYDUS CADILA
25.15.1 COMPANY OVERVIEW
25.15.2 REVENUE ANALYSIS
25.15.3 GEOGRAPHIC PRESENCE
25.15.4 PRODUCT PORTFOLIO
25.15.5 RECENT DEVELOPEMNTS
25.16 HIKMA PHARMACEUTICALS
25.16.1 COMPANY OVERVIEW
25.16.2 REVENUE ANALYSIS
25.16.3 GEOGRAPHIC PRESENCE
25.16.4 PRODUCT PORTFOLIO
25.16.5 RECENT DEVELOPEMNTS
25.17 MALLINCKRODT PHARMACEUTICALS
25.17.1 COMPANY OVERVIEW
25.17.2 REVENUE ANALYSIS
25.17.3 GEOGRAPHIC PRESENCE
25.17.4 PRODUCT PORTFOLIO
25.17.5 RECENT DEVELOPEMNTS
25.18 GLENMARK PHARMACEUTICALS
25.18.1 COMPANY OVERVIEW
25.18.2 REVENUE ANALYSIS
25.18.3 GEOGRAPHIC PRESENCE
25.18.4 PRODUCT PORTFOLIO
25.18.5 RECENT DEVELOPEMNTS
25.19 ALLERGAN (ABBVIE)
25.19.1 COMPANY OVERVIEW
25.19.2 REVENUE ANALYSIS
25.19.3 GEOGRAPHIC PRESENCE
25.19.4 PRODUCT PORTFOLIO
25.19.5 RECENT DEVELOPEMNTS
25.20 BOEHRINGER INGELHEIM
25.20.1 COMPANY OVERVIEW
25.20.2 REVENUE ANALYSIS
25.20.3 GEOGRAPHIC PRESENCE
25.20.4 PRODUCT PORTFOLIO
25.20.5 RECENT DEVELOPEMNTS
25.21 NOSTRUM LABORATORIES
25.21.1 COMPANY OVERVIEW
25.21.2 REVENUE ANALYSIS
25.21.3 GEOGRAPHIC PRESENCE
25.21.4 PRODUCT PORTFOLIO
25.21.5 RECENT DEVELOPEMNTS
25.22 SANDOZ (A NOVARTIS DIVISION)
25.22.1 COMPANY OVERVIEW
25.22.2 REVENUE ANALYSIS
25.22.3 GEOGRAPHIC PRESENCE
25.22.4 PRODUCT PORTFOLIO
25.22.5 RECENT DEVELOPEMNTS
25.23 AUROBINDO PHARMA
25.23.1 COMPANY OVERVIEW
25.23.2 REVENUE ANALYSIS
25.23.3 GEOGRAPHIC PRESENCE
25.23.4 PRODUCT PORTFOLIO
25.23.5 RECENT DEVELOPEMNTS
25.24 WOCKHARDT
25.24.1 COMPANY OVERVIEW
25.24.2 REVENUE ANALYSIS
25.24.3 GEOGRAPHIC PRESENCE
25.24.4 PRODUCT PORTFOLIO
25.24.5 RECENT DEVELOPEMNTS
25.25 ORCHID PHARMA
25.25.1 COMPANY OVERVIEW
25.25.2 REVENUE ANALYSIS
25.25.3 GEOGRAPHIC PRESENCE
25.25.4 PRODUCT PORTFOLIO
25.25.5 RECENT DEVELOPEMNTS
25.26 AMPHASTAR PHARMACEUTICALS, IN
25.26.1 COMPANY OVERVIEW
25.26.2 REVENUE ANALYSIS
25.26.3 GEOGRAPHIC PRESENCE
25.26.4 PRODUCT PORTFOLIO
25.26.5 RECENT DEVELOPEMNTS
25.27 ALEMBIC PHARMACEUTICALS
25.27.1 COMPANY OVERVIEW
25.27.2 REVENUE ANALYSIS
25.27.3 GEOGRAPHIC PRESENCE
25.27.4 PRODUCT PORTFOLIO
25.27.5 RECENT DEVELOPEMNTS
25.28 ALKEM LABORATORIES
25.28.1 COMPANY OVERVIEW
25.28.2 REVENUE ANALYSIS
25.28.3 GEOGRAPHIC PRESENCE
25.28.4 PRODUCT PORTFOLIO
25.28.5 RECENT DEVELOPEMNTS
25.29 TORRENT PHARMACEUTICALS
25.29.1 COMPANY OVERVIEW
25.29.2 REVENUE ANALYSIS
25.29.3 GEOGRAPHIC PRESENCE
25.29.4 PRODUCT PORTFOLIO
25.29.5 RECENT DEVELOPEMNTS
25.30 PAR PHARMACEUTICAL.
25.30.1 COMPANY OVERVIEW
25.30.2 REVENUE ANALYSIS
25.30.3 GEOGRAPHIC PRESENCE
25.30.4 PRODUCT PORTFOLIO
25.30.5 RECENT DEVELOPEMNTS
25.31 MERCK & CO., INC
25.31.1 COMPANY OVERVIEW
25.31.2 REVENUE ANALYSIS
25.31.3 GEOGRAPHIC PRESENCE
25.31.4 PRODUCT PORTFOLIO
25.31.5 RECENT DEVELOPEMNTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOU.S. CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
26. RELATED REPORTS
27. CONCLUSION
28. QUESTIONNAIRE
29. ABOUT DATA BRIDGE MARKET RESEARCH
